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Abstract: The glycogen storage disease type II (GSD-II), or Pompe disease, is due to the deﬁ  cit 
of lysosomal glycogen degradation enzyme acid α-glucosidase (GAA). In infants, Pompe disease 
is characterized by prominent hypotonia, muscle weakness, motor delay, feeding problems, 
and respiratory and cardiac insufﬁ  ciency. In a retrospective study, the median age at death was 
8.7 months. Enzyme replacement therapy with recombinant human GAA is recently used to treat 
patients with Pompe disease, and has been shown to prolong survival, reverse cardiomyopathy, 
and improve motor function. This article brieﬂ  y reviews the history and manifestations of Pompe 
disease, and then focuses on the development of the drug for Pompe disease, alglucosidase alfa. 
Current status of treatment and future developments are also discussed.
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History
Pompe disease was ﬁ  rst described by Dr. Pompe almost 55 years ago in a 7-month-old 
girl with cardiomyopathy, in whom massive accumulation of glycogen in vacuoles was 
observed in all tissues examined (Pompe 1932). After identiﬁ  cation of lysosome by 
de Duve in 1963 (De Duve 1963, 2005), Pompe disease became the ﬁ  rst recognized 
lysosomal storage disorder (LSD) when it was found that the disease was due to the 
deﬁ  cit of lysosomal glycogen degradation enzyme acid α-glucosidase (GAA, EC 
3.2.1.20) (Hers 1963). Pompe disease is formally named glycogen storage disease 
type II (GSD-II), but most other types of GSDs are caused by defects in the cytosolic 
glycogen cleavage or synthesis pathways (Shin 2006). Pompe disease is remotely 
related to Danon disease, also known as X-linked vacuolar cardiomyopathy and 
myopathy (Danon et al 1981). In Danon disease, lysosomal glycogen storage is caused 
by mutation of the lysosome-associated membrane protein-2 (LAMP-2) gene, and 
there is no GAA deﬁ  ciency (Nishino et al 2000).
Clinical manifestation
Pompe disease is usually classiﬁ  ed into infantile-onset and late-onset for convenience, 
although there is clearly a continuum in disease severity ranging from the most 
severe classical infantile-onset Pompe disease (IOPD), to the mildest adult-onset 
Pompe disease (Hirschhorn and Reuser 2001; Raben et al 2002). In the Netherlands, 
a combined frequency for all type of Pompe disease was estimated to be 1 in 50,000 
(Poorthuis et al 1999). After screening for seven mutations in an ethnically diverse 
population, a study in New York suggested an incidence of 1 in 40,000 (Martiniuk et al 
1998). The incidence of Pompe disease in certain ethnic groups, for example in Israel 
(Bashan et al 1988) and in Taiwan (Lin and Shieh 1996), may be higher. Patients of 
IOPD are usually recognized at the age of 3–5 months because of a respiratory infection 
(Hirschhorn and Reuser 2001; Marsden 2005). A chest X-ray at that time may show 
cardiomegaly which leads to further check-up and diagnosis of IOPD. On physical 
examination, head lag during a traction from the supine position is usual prominent. 
Although weakness of extremities or trunk can usually be conﬁ  rmed retrospectively Biologics: Targets & Therapy 2007:1(3) 196
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at the age of 2–3 months (Marsden 2005; Kishnani et al 
2006a), only rarely do these signs trigger an investigation 
of affected children (Howell et al 2006). The lack of power 
for early diagnosis for hypotonia can be explained both by 
parental lack of experience and by children’s large individual 
variation in normal development.
Because of the late diagnosis in most cases of IOPD, 
it is not clear how early signs of cardiomegaly can be 
detected. Pompe disease diagnosis at the newborn stage has 
been described, but was not found in a recent large-scale 
natural history study (Kishnani et al 2006a). However, 
recently a newborn baby was diagnosed in Hong Kong 
because of respiratory distress shortly after birth (personal 
communication to Dr. Grace Poon). Large QRS complexes 
and short PR interval have been the cardinal diagnostic 
criteria in EKG (Ansong et al 2006), but the sensitivity 
of short PR interval is not high. In echocardiography, the 
thickening of the ventricular wall and the interventricular 
septum are marked, the ventricular cavities are very small 
and the outﬂ  ow tract can be obliterated. Symptomatic outﬂ  ow 
tract obstruction may occur shortly after the diagnosis of 
IOPD. A careful management of this condition is critical, 
and an adequate use of diuretics and β-blockers can usually 
help the affected baby to overcome this symptom, but acute 
death is also possible (Kishnani et al 2006c). As the disease 
advances, the heart becomes more dilated and obstruction 
sign can disappear. Occasionally, overt cardiac failure leads 
to death.
According to the recent natural history review, the 
progression of IOPD is very fast, and the gap between the 
median age at diagnosis and the median age of ﬁ  rst use of 
ventilator was only 1.2 months (Kishnani et al 2006a), and 
between median age at diagnosis and death was 2.4 months 
in a Dutch study (van den Hout et al 2003). The major illness 
beyond cardiac obstruction would be respiratory failure. 
Weakness of the respiratory muscles and cough reﬂ  ex are the 
major causes of respiratory problem, and once these children 
are intubated, they rapidly become ventilator dependent. 
If the lives of patients could be prolonged, for example by 
ventilator support or enzyme replacement (to be discussed 
later), symptoms related to other organ systems may 
present (Kishnani et al 2006c). Weakness of the diaphragm 
makes hygiene of the lower pulmonary segments difﬁ  cult. 
Paradoxical respiration, that is, elevation of the diaphragm 
during inspiration, is also common. Dysfunction of the 
gastrointestinal tract is a serious complication. Dysphagia, 
gastro-esophageal reflux, delayed gastric empty time, 
and intestinal dysfunction are all likely. If swallowing is 
problematic, jejunostomy rather than gastrostomy will be 
necessary to achieve adequate feeding without causing 
aspiration (Kishnani et al 2006c). The involvements of 
other organ systems besides the muscle are not a surprise, 
since glycogen storage is universal throughout the body. 
Four cases with IOPD revealed a hearing loss which may 
be due to a problem in the cochlea or middle ear (Van den 
Hout et al 2004). Brain development is also a concern, since 
excessive glycogen storage has been found in both neurons 
and glial cells (Gambetti et al 1971; Sakurai et al 1974). 
However, catch up in brain myelination after stabilization 
of the patients has also been reported (Chien et al 2006). 
In conclusion, without speciﬁ  c treatment, neither any of 
the above-mentioned efforts, nor rehabilitation or dietary 
management could alter the outcome of IOPD.
Molecular basis
The GAA gene is located on chromosome 17q25. The gene 
encodes a peptide of 952 amino acids with nonglycosylated 
weight of 105 kDa (Hirschhorn and Reuser 2001). Extensive 
modiﬁ  cations of the protein occurs afterwards, which include 
glycosylation and proteolytic processing, resulting in the 76 
and 70 kDa mature GAA protein (Hirschhorn and Reuser 
2001). More than 70 mutations have been found on the GAA 
gene (Raben et al 2002; Hermans et al 2004). The mutations 
are spread over the gene. Several common mutations are 
found in different ethnic groups, including the IVS1 t-13g 
in Caucasian patients with adult-onset disease (Huie et al 
1994; Boerkoel et al 1995; Kroos et al 1995), the Arg854X 
mutation in African Americans (Tsujino et al 2000), and the 
Asp645Glu mutation in Chinese patients from Taiwan (Lin 
and Shieh 1996; Ko et al 1999). A few of the mutations 
have been expressed in cultured cells and the GAA activities 
obtained can be correlated to the phenotypes or the severity 
of the disease (Hermans et al 2004).
Laboratory diagnosis
Laboratory diagnosis depends on the measurement of GAA 
activity in blood or tissues. The assay used to measure GAA 
activity usually employs an artiﬁ  cial ﬂ  uorogenic substrate, 
4-methylumbelliferyl-α-D-glucopyranoside (4-MUG), but 
several α-glucosidase (E.C. 3.2.1.20) isoenzymes especially 
maltase-glucoamylase (MGA) in blood and hematopoietic 
cells contribute to the observed reaction (Taniguchi et al 1978; 
Shin et al 1985; Hirschhorn and Reuser 2001). Therefore 
the assay has to be done either in lymphocytes or in skin 
ﬁ  broblasts which have activity at pH 4.0 mainly due to GAA 
(Taniguchi et al 1978; Shin et al 1985). However, lymphocyte Biologics: Targets & Therapy 2007:1(3) 197
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preparations are often contaminated by leukocytes, and the 
resulting falsely high residual activity cannot be used to 
predict phenotype. Recently, immobilized antibodies have 
been used to remove the interfering enzymes (Schram et al 
1979; Umapathysivam et al 2000; Umapathysivam et al 
2001). GAA speciﬁ  c activity measured in this way, together 
with data from skin ﬁ  brobasts, may make it possible to 
predict the age of onset of Pompe disease (Umapathysivam 
et al 2005).
The start of enzyme replacement 
therapy
The ﬁ  rst successful attempt towards a speciﬁ  c pharmaceutical 
treatment of LSD was in Gaucher disease. The enzyme 
deficient in Gaucher disease, the β-glucosidase, was 
ﬁ  rst puriﬁ  ed from placenta in 1974 (Brady et al 1974; Furbish 
et al 1977). It was discovered later that it was necessary 
to modify the oligosaccharide moieties on the enzyme to 
facilitate its macrophage targeting. The exogenous enzyme 
molecules are internalized and shipped in vacuoles through 
receptor-mediated mechanisms. These vacuoles then fuse 
with the lysosomes elegantly to correct their intrinsic 
defect. These processes make exogenous supplementation 
of lysosomal enzymes, or enzyme replacement therapy 
(ERT), an efﬁ  cient way to treat LSD (Brady 2006). Placental 
β-glucosidase was approved for this use by the US Food 
and Drug Administration (FDA) in 1991, and was later 
replaced by a Chinese hamster ovary (CHO) cell-produced 
recombinant β-glucosidase in 1994 (Barranger and O’Rourke 
2001). More than 4000 patients all over the world have been 
treated with this drug (Rosenbloom et al 2005). ERT have 
been developed for several other diseases, including Fabry 
disease, mucopolysaccharidosis (MPS) type I, MPS type II 
and MPS type IV (Beck 2007).
Recombinant human GAA (rhGAA) 
production
Previously, there was no effective treatment for Pompe 
disease. Bone marrow transplantation seems not to work. 
A combined treatment including dietary management 
and physical therapy has not shown signiﬁ  cant effects in 
IOPD patients (Bembi et al 2003). Recently, two groups 
of researchers followed different approaches to produce a 
recombinant GAA protein. One group used the innovative 
approach of transgenic production of the therapeutic enzyme 
in mammalian milk (Bijvoet et al 1996). The human GAA 
cDNA was placed under the control of the αS1-casein 
promoter and expressed in mice. The recombinant GAA 
puriﬁ  ed from mice milk was internalized via the mannose 
6-phosphate receptor and corrected the enzyme deﬁ  ciency 
in ﬁ  broblasts from patients (Bijvoet et al 1996). The mouse 
transgenic construct was later modiﬁ  ed for higher production, 
and the enzyme, when injected intravenously, corrects the 
GAA deﬁ  ciency in heart and skeletal muscles of GSD-II 
knockout mice (Bijvoet et al 1998). This success in producing 
recombinant GAA from mice milk led to the industrial 
manufacturing of GAA from rabbit. In the GAA knockout 
mice, a single intravenous infusion of the enzyme gave a 
full correction of GAA deﬁ  ciency in all mice tissues except 
brain (Bijvoet et al 1999). Weekly enzyme infusions over 
6 months resulted in degradation of lysosomal glycogen in 
the heart and muscle. The results then led to a clinical trial 
with rabbit milk recombinant enzyme.
Another study group chose the more traditional approach 
of expressing the recombinant enzyme in CHO cells (Van 
Hove et al 1996, 1997). This enzyme was effectively taken 
up by ﬁ  broblasts from Pompe patients (Van Hove et al 1996), 
restoring normal levels of GAA and glycogen. By intravenous 
infusion, the enzyme can be targeted to the heart and liver 
efﬁ  ciently in guinea pigs (Van Hove et al 1996). Pre-clinical 
studies for CHO enzyme were conducted in GAA-deﬁ  cient 
Japanese quails. Uptake and targeting of the enzyme were 
ﬁ  rst tested in quail ﬁ  broblast (Yang et al 1998). The results of 
the treatment were very encouraging; besides improvements 
in muscle histology, there was clear gain in function (Kikuchi 
et al 1998). The quails were treated at the age of 4 weeks. 
After 7 injections over a 16-day period, the sham-treated 
quails exhibited progressive myopathy and could not lift 
their wings or right themselves from the supine position. 
However, treated birds could ﬂ  ap their wings, and one bird 
ﬂ  ew up more than 100 cm.
Dosage and frequency
However, these pre-clinical studies also disclosed one truth: 
high doses of the recombinant enzyme were required for 
a positive response. For example, in the quail study, the 
effect of high-dose treatment (14 mg/kg) was much better 
than low-dose treatment (4.2 mg/kg) (Kikuchi et al 1998). 
There was an additional experiment with intermediate doses 
(5.7–9 mg/kg) and extended treatment. Despite signiﬁ  cantly 
improved histopathology of affected tissues, the quails in this 
group showed no clinical improvement in muscle strength 
and were not able to ﬂ  ap their wings or ﬂ  y (Kikuchi et al 
1998). The requirement in Pompe disease of large amount of 
enzyme to correct muscle pathology is in contrast to the small Biologics: Targets & Therapy 2007:1(3) 198
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dose necessary to correct several other LSDs. For example, 
the regular dosage for Fabry disease is 1 mg/kg (Wilcox et al 
2004). Currently, why a high dose of the enzyme is required in 
Pompe disease is not fully known. One possible explanation 
is that the paucity of mannose 6-phosphate receptor in the 
muscle tissues prevents efﬁ  cient uptake of the enzyme (Wenk 
et al 1991; Raben et al 2003). This large requirement of 
enzyme should have posed a challenge in both the production 
and the cost of the drug, but currently these issues have been 
solved. Problems, such as immunologic responses, arising 
from the infusion of large amounts of foreign protein, will 
be discussed later.
Clinical trials
Early clinical trials for rhGAA in IOPD patients revealed 
promising results. With the rabbit milk rhGAA, 4 patients 
were treated for 36 weeks and ﬁ  rst reported in 2000 (Van 
den Hout et al 2000). Doses started from 15–20 mg/kg to 
40 mg/kg once weekly. The most prominent effect was on the 
heart: the left ventricular mass index decreased to less than 
30% of baseline within 36 weeks. Skeletal muscle function 
and strength also improved in all patients. One patient treated 
at the age of 2.5 months was cross-reactive-immunological-
material (CRIM) negative, but her improvement continued 
over the study period. Only one patient gained the normal 
major motor development. Therefore the researchers 
recommended that treatment be started early, before the 
destruction of muscle architecture, for successful outcome of 
treatment (Van den Hout et al 2004). The long-term outcomes 
of 2 cases were further described, and survival time under 
therapy was 55 and 58 months (Klinge et al 2005a; Klinge 
et al 2005b). There were only mild infusion-associated 
reactions during the follow-up period. Both patients sat, 
and their mental development was normal. The production 
of milk rhGAA was later discontinued.
The ﬁ  rst clinical trial (phase I/II) with CHO cell-produced 
rhGAA was done in 3 patients (Amalﬁ  tano et al 2001). They 
received twice-weekly infusion of rhGAA at a dosage of 
5 mg/kg for 14–17 months. Adverse reactions were mild and 
could be resolved by a pre-infusion dose of antihistamine. 
Steady decrease in heart size was universal. Improvements 
in skeletal muscle function were also noted. One patient 
walked independently from 12 months of age. A high titer 
of anti-rhGAA antibody developed in two patients who had 
no detectable GAA protein by Western blot analysis (CRIM 
negative). This promising preliminary result triggered a 
scaled-up production of the enzyme and the phase II trial in 
8 patients with IOPD (Kishnani et al 2006b). Dosages were 
either 10–20 mg/kg weekly or 20 mg/kg every 2 weeks. 
Safety of the drug was first confirmed. Although IgG 
antibodies to rhGAA developed in all 8 patients by week 8 
of treatment, after 52 weeks of treatment the antibody titers 
either decreased or remained unchanged. Six of 8 patients 
were alive after the study period. Clinical improvements 
included ameliorated cardiomyopathy, improved growth and 
cognition, and 3 patients walked independently. Even though 
4 patients subsequently died, in view of the fact that this is 
a rapidly fatal disease if left untreated, rhGAA did change 
the clinical course of the disease.
Finally a phase III trial with the CHO cell rhGAA started. 
This trial enrolled 18 patients younger than 6 months of age 
worldwide (Kishnani et al 2007). The dosage was 20 or 
40 mg/kg every other week. After treatment for 52 weeks, 
all patients survived to 18 months of age. There was no 
clear advantage of the 40 mg/kg dose. A Cox proportional 
hazards analysis demonstrated that the treatment decreased 
risk of death by 99%. This clinical trial led to FDA approval 
of Alglucosidase Alfa (Myozyme®, Genyzme Corporation). 
The recommended dose is 20 mg/kg every other week. For 
late-onset forms of Pompe disease, rhGAA both from rabbit 
milk or from CHO cells has shown preliminary therapeutic 
effects, although the number of reported cases is still small 
(Van den Hout et al 2004; Winkel et al 2004).
Disadvantages: high required dosage 
and antibody formation
The requirement of high dose of rhGAA to treat Pompe 
disease, almost 10 fold of other diseases, is also unique. 
The volume of muscle tissue to treat is large, as mentioned. 
Lower efﬁ  ciency in enzyme uptake by the muscular system 
may be another factor. Both mediated by the mannose 
6-phosphate receptor, the cardiac muscles are much more 
efﬁ  cient in enzyme uptake than the skeletal muscles (Wenk 
et al 1991; Raben et al 2003). Infusion of large amount of 
foreign proteins may causes problems. One case report 
described the development of nephrotic syndrome in a 
patient receiving a daily infusion of 10 mg/kg of rhGAA 
(Hunley et al 2004). Life-threatening anaphylactic reactions 
including anaphylactic shock have been observed in patients 
during alglucosidase alfa treatment. Antibody development 
is universal in treated patients, most within the ﬁ  rst 3 months 
of treatment (Kishnani et al 2006b). Antibodies to the infused 
enzyme have been observed in other ERTs, but rarely cause 
trouble (Rosenberg et al 1999; Wilcox et al 2004). In IOPD, 
some patients were CRIM negative. Antibody titers seemed to 
be higher in those cases (Amalﬁ  tano et al 2001). Although the Biologics: Targets & Therapy 2007:1(3) 199
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surge of antibody titers in some patients has been suspected 
to be related to the loss of therapeutic effect (Amalﬁ  tano 
et al 2001), the case number is too small to conclude whether 
CRIM status or the antibody titer will be an untoward 
prognostic factor in treatment of Pompe disease.
CRIM status may indeed reflect the severity of the 
disease. It is suggested that the better the clinical status 
before initiation of treatment, the better the outcome. With 
a milder or later-onset disease, application of alglucosidase 
alfa therapy promises a good likelihood of recovery. In a 
recent paper, the muscle pathologies of Pompe disease were 
classiﬁ  ed into 5 stages (Thurberg et al 2006). Landmarks 
in the staging include appearance of intra-lysosomal or 
cytoplasmic glycogen, integrity of the mitochondria, and 
myoﬁ  bril dissociation (Thurberg et al 2006). It is likely that 
muscle cells may be not able to recover when the damage 
is too advanced.
Early treatment
Another view in considering the relationship between 
treatment effect and disease severity is the timing of treatment. 
That is, treatment should be started before the threshold 
of muscle pathology been reached (Thurberg et al 2006). 
A more severe disease or more rapid disease progression 
requires earlier treatment. Clinical conditions like respiratory 
failure, mechanical ventilation, or immobilization are almost 
fatal regardless of treatment. However, from a recent IOPD 
natural history survey, the median age at diagnosis was 
4.7 months, while the median age of ﬁ  rst ventilator use 
was 5.9 months, only one month apart (van den Hout et al 
2003; Kishnani et al 2006a). On the other hand, previous 
experience in Pompe disease treatment has demonstrated 
that drug effect takes 2–3 months to appear. For example, the 
decrease in heart size usually takes 3 months after initiation 
of treatment (Amalﬁ  tano et al 2001). Therefore it is likely 
that a poor early clinical course will destroy the therapeutic 
effect. In the past few years, a number of IOPD patients have 
been treated in different clinical trials or by compassionate 
use. Because of the difﬁ  culty of getting into treatment, 
many cases had late treatment. Partial reversal of disease 
manifestations, including being bedridden or wheelchair 
bound, feeding problems, or even ventilator dependence were 
not uncommon. In those partially treated cases, complications 
included bone fracture, heart arrhythmia (preexisting ectopy 
including premature ventricular contractions, perhaps 
caused by ﬁ  brous tissue deposition in the myocardium), 
and problems in brain myelination (Cook et al 2006; Case 
et al 2007). After the formal launch of alglucosidase alfa, 
the situation should improve. However, patients receiving 
ERT may need a follow-up to see the long-term safety and 
efﬁ  cacy of alglucosidase alfa.
Currently accumulating evidence suggests that early 
treatment for IOPD should be beneficial. However, as 
discussed in previously sections, early diagnosis of IOPD 
is rarely achieved unless there is positive family history, 
because early signs are non-speciﬁ  c. Therefore, screening 
for IOPD in very early ages of babies is the best and only 
choice. Laboratory diagnosis of Pompe disease, as discussed 
in a previous section, has been difﬁ  cult. But in the past few 
years there were signiﬁ  cant progresses in this ﬁ  eld. First is 
the employment of blood spot as the source for lysosomal 
enzyme assays (Chamoles et al 2001). With an extended 
enzyme reaction time, a tiny amount of blood lysate from 
1/8 inch spots could serve several assays (Chamoles et al 
2002a, b). The most critical invention is the use of inhibitors 
(maltose or acarbose) in the assay, so the assay could be 
performed without blood cell separation (Chamoles et al 
2004; Li et al 2004). Very important information will be 
generated from the screening programs, for example, what 
percentage of IOPD can have a satisfactory outcome if treated 
early, or whether CRIM-negative patients can be rescued if 
treated early.
Future aspects in ERT
Lastly, the failure of the rabbit milk product has shown the 
difﬁ  culty of developing transgenic methods to produce large 
molecule therapeutic agents. It is not clear why the company 
withdraw the project, since early clinical trials disclosed 
comparable treatment effect to the other product. There 
may be difﬁ  culties or high cost in maintaining the herd or in 
puriﬁ  cation of the product from the large quantities of milk 
protein. However, the method of standardization in culturing 
cells does look more feasible than raising animals. Several 
recent enzyme products are produced from human ﬁ  broblasts. 
It has been argued whether human cell products will be better 
than animal cell products, for example the agalsidase beta 
from CHO cells (Fabrazyme®, Genzyme Corporation) and 
agalsidase alfa from human ﬁ  broblasts (Replagal®, Shire) 
(Beck 2002). But the ﬁ  rst and successful ERT product, the 
imiglucerase (Cerezyme®, Genzyme Corporation), is from 
CHO cells. The infusion reaction for imiglucerase is transient 
and mild, and rarely interferes with treatment. Therefore, 
contamination of animal cell proteins seems negligible. The 
question of the efﬁ  cacy of ﬁ  broblasts enzymes cannot be 
easily answered because of the large differences in disease 
pathophysiology.Biologics: Targets & Therapy 2007:1(3) 200
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Future development in ERT therapy will need to overcome 
other difﬁ  culties especially in targeting the enzyme. For 
example, conjugation of mannose 6-phosphate-containing 
oligosaccharides to acid alpha-glucosidase improves the 
delivery to muscles and the clearance of glycogen in pompe 
mice (Zhu et al 2004, 2005). Also, a tag with an acidic 
oligopeptide may enhance drug delivery to bone (Nishioka 
et al 2006), and a phosphorylated rhGALNS can be delivered 
to multiple tissues, including bone, implying a potential 
enzyme replacement treatment for mucopolysaccharidosis 
type IVA (Tomatsu et al 2007).
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